| Project/Area Number |
20591700
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | National Institute of Advanced Industrial Science and Technology |
|---|
Principal Investigator |
TSURUSHIMA Hideo National Institute of Advanced Industrial Science and Technology, 大学院・人間総合科学研究科, 准教授 (50315470)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 脳血管内外科学 / ナノ粒子 / DDS / active targeting / リポソーム / 虚血性疾患 / 血管形成術 / 再狭窄予防 / 糖鎖 / シポソーム / 糖鎖-レクチン蛋白質親和性 / drug delivery system / active targeting DDS / ドキソルビシン / 血管狭窄 / 血管形成術後再狭窄 / 血管狭窄予防 |
|---|
| Research Abstract |
Restenosis remains a serious complication that can occur after angioplasty. This study investigated the efficiency of an active targeting chemotherapy using liposomes,including doxorubicin, which surface was decorated with sialyl Lewis X (SLX), (Dox-Lipo-SLX), to prevent stenosis after angioplasty. Its delivery was controlled via the affinity between SLX and E-selectin proteins, which are expressed on injured arteries. In vitro experiments confirmed that doxorubicin accumulated owing to Dox-Lipo-SLX by adhering to E-selectin-positive cells. Rats with balloon-injured arteries were intravenously injected with Dox-Lipo-SLX. A significant doxorubicin accumulation was observed on the injured vessel walls in rats treated with Dox-Lipo-SLX. The efficiency of stenosis prevention was evaluated. The residual lumen area of the group treated with Dox-Lipo-SLX was significantly larger than all of the other groups. These results demonstrate that an active targeting drug delivery system with Dox-Lipo-SLX effectively prevents stenosis after angioplasty.
|
